Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2008

01-10-2008 | Original Article

Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

Authors: Stephan Good, Martin A. Walter, Beatrice Waser, Xuejuan Wang, Jan Müller-Brand, Martin P. Béhé, Jean-Claude Reubi, Helmut R. Maecke

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2008

Login to get access

Abstract

Purpose

Diethylenetriamine-pentaacetic acid (DTPA)-coupled minigastrins are unsuitable for therapeutic application with the available β-emitting radiometals due to low complex stability. Low tumour-to-kidney ratio of the known radiopharmaceuticals is further limiting their potency. We used macrocyclic chelators for coupling to increase complex stability, modified the peptide sequence to enhance radiolytic stability and studied tumour-to-kidney ratio and metabolic stability using 111In-labelled derivatives.

Methods

Gastrin derivatives with decreasing numbers of glutamic acids were synthesised using 111In as surrogate for therapeutic radiometals for in vitro and in vivo studies. Gastrin receptor affinities of the natIn-metallated compounds were determined by receptor autoradiography using 125I-CCK as radioligand. Internalisation was evaluated in AR4-2J cells. Enzymatic stability was determined by incubating the 111In-labelled peptides in human serum. Biodistribution was performed in AR4-2J-bearing Lewis rats.

Results

IC50 values of the natIn-metallated gastrin derivatives vary between 1.2 and 4.8 nmol/L for all methionine-containing derivatives. Replacement of methionine by norleucine, isoleucine, methionine-sulfoxide and methionine-sulfone resulted in significant decrease of receptor affinity (IC50 between 9.9 and 1,195 nmol/L). All cholecystokinin receptor affinities were >100 nmol/L. All 111In-labelled radiopeptides showed receptor-specific internalisation. Serum mean-life times varied between 2.0 and 72.6 h, positively correlating with the number of Glu residues. All 111In-labelled macrocyclic chelator conjugates showed higher tumour-to-kidney ratios after 24 h (0.37–0.99) compared to 111In-DTPA-minigastrin 0 (0.05). Tumour wash out between 4 and 24 h was low. Imaging studies confirmed receptor-specific blocking of the tumour uptake.

Conclusions

Reducing the number of glutamates increased tumour-to-kidney ratio but resulted in lower metabolic stability. The properties of the macrocyclic chelator-bearing derivatives make them potentially suitable for clinical purposes.
Appendix
Available only for authorised users
Literature
1.
Wank SA, Pisegna JR, de Weerth A. Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann N Y Acad Sci 1994;713:49–66.PubMedCrossRef
2.
Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med 2006;84:544–50.PubMedCrossRef
3.
Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745–81.PubMed
4.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef
5.
Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F, et al. Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 1997;112:1197–205.PubMedCrossRef
6.
Reubi J, Waser B. Unexpected high incidence of cholecystokinin B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 1996;67:644–7.PubMedCrossRef
7.
Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377–86.PubMed
8.
Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30:781–93.PubMed
9.
Gotthardt M, Behe MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2006;33:1273–9.PubMedCrossRef
10.
Gotthardt M, Behe MP, Grass J, Bauhofer A, Rinke A, Schipper ML, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 2006;13:1203–11.PubMedCrossRef
11.
Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 1998;25:424–30.PubMedCrossRef
12.
de Jong M, Bakker W, Bernard B, Valkema R, Kwekkeboom D, Reubi J, et al. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081–7.PubMed
13.
Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029–44.PubMed
14.
Reubi JC. CCK receptors in human neuroendocrine tumors: clinical implications. Scand J Clin Lab Invest Suppl 2001;234:101–4.PubMed
15.
Kwekkeboom DJ, Bakker WH, Kooij PP, Erion J, Srinivasan A, de Jong M, et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur J Nucl Med 2000;27:1312–7.PubMedCrossRef
16.
Reubi JC, Maecke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 2005;46:67S–75S.PubMed
17.
von Guggenberg E, Behe M, Behr TM, Saurer M, Seppi T, Decristoforo C. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Na-His)acetic acid-modified [d-Glu1]-minigastrin. Bioconjug Chem 2004;15:864–71.CrossRef
18.
Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140–6.PubMedCrossRef
19.
Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399–418.PubMedCrossRef
20.
Nock BA, Maina T, Behe M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/Gastrin receptor-targeted tumor imaging with 99mTc-labeled minigastrin analogs. J Nucl Med 2005;46:1727–36.PubMed
21.
Aloj L, Caraco C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485–94.PubMed
22.
Behr TM, Behe MP. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97–109.PubMedCrossRef
23.
Harrison A, Walker C, Parker D. The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Nucl Med & Biol 1991;18:469–76.
24.
Eisenwiener KP, Powell P, Maecke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett 2000;10:2133–5.PubMedCrossRef
25.
Good S, Maecke H. Kinetics of formation and dissociation of two DOTA-based chelator conjugates with 177Lu. Eur J Nucl Med Mol Imaging 2003;30(Suppl 2):S319.
26.
Good S, Maecke H. Stability and kinetics of formation of two macrocyclic chelator-conjugates. Nuklearmedizin 2004;43:A11.
27.
Heppeler A, Froidevaux S, Mäcke HR, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chemistry A European Journal 1999;5:1016–23.
28.
Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 2002;13:530–41.PubMedCrossRef
29.
Reubi J, Waser B, Schaer J, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481–90.PubMedCrossRef
30.
Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969–77.PubMed
31.
Christophe J. Pancreatic tumoral cell line AR42J: an amphicrine model. Am J Physiol 1994;266:G963–G71.PubMed
32.
Wild D, Schmitt JS, Ginj M, Maecke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30:1338–47.PubMedCrossRef
33.
Storch D, Behe M, Walter MA, Chen J, Powell P, Mikolajczak R, et al. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 2005;46:1561–9.PubMed
34.
Maecke H, Good S. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vertes A, Nagy S, Klencsar Z, editors. Handbook of nuclear chemistry. Vol. 4. Netherlands; 2003, p. 279–314.
35.
Bogni A, Bombardieri E, Iwata R, Cadini L, Pascali C. Stability of l-[S-methyl-11C]methionine solutions. J Radioanal Nucl Chem 2003;256:199–203.CrossRef
36.
Liu S, Edwards DS. Stabilization of 90Y-labeled DOTA-biomolecule conjugates using gentisic acid and ascorbic acid. Bioconjug Chem 2001;12:554–8.PubMedCrossRef
37.
Good S, Maecke H, Merlo A, Reubi JC. Development of NK-1 receptor mediated radiopharmaceuticals. Nuklearmedizin 2004;43:A7.
38.
Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001;28:1421–9.PubMedCrossRef
39.
Trejtnar F, Laznicek M. Analysis of renal handling of radiopharmaceuticals. Q J Nucl Med 2002;46:181–94.PubMed
40.
de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of 111In-DTPA-octreotide. J Nucl Med 2005;46:1696–700.PubMed
41.
Behe M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed
42.
von Guggenberg E, Rupprich M, Virgolini I, Decristoforo C. 99mTc-HYNIC-Minigastrin: improved in vitro and in vivo properties of a short chain analogue. Eur J Nucl Med Mol Imaging 2005;32(Suppl 1):S35.
43.
Behe M, Reubi JC, Nock B. Evaluation of a DOTA-minigastrin derivative for therapy and diagnosis for CCK-2 receptor positive tumours. Eur J Nucl Med Mol Imaging 2005;32(Suppl 1):S78.
44.
Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201–12.PubMedCrossRef
Metadata
Title
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours
Authors
Stephan Good
Martin A. Walter
Beatrice Waser
Xuejuan Wang
Jan Müller-Brand
Martin P. Béhé
Jean-Claude Reubi
Helmut R. Maecke
Publication date
01-10-2008
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0803-4

Other articles of this Issue 10/2008

European Journal of Nuclear Medicine and Molecular Imaging 10/2008 Go to the issue

Original Article

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

Focus on

Oesophageal cancer: can imaging improve its assessment?

Original Article

Non-invasive estimation of hepatic blood perfusion from H2 15O PET images using tissue-derived arterial and portal input functions

Original article

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET–CT: a comparative study

Editorial

How much CT is needed in nuclear medicine

Original Article

Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases